HTLV Infections

This is an infection caused by a virus called HTLV. It can sometimes lead to certain types of leukemia or lymphoma, which are cancers of the blood cells. It's important to see a doctor if you think you might have this, as it can be serious.

Condition

What people with HTLV Infections report

Every report comes from a Lived member, sent anonymously.

NameHow it went

No reports yet

Add what worked for you with the search bar below

About HTLV Infections

What It Is

HTLV infections are caused by human T-lymphotropic viruses (HTLV), a small family of retroviruses that infect a type of white blood cell called the T cell. Once someone has the virus, it stays in the body for life, carried inside infected cells. There are two main human types. HTLV-1 is the one linked to disease. HTLV-2 is less common and much less likely to cause health problems. (The scientific family, deltaretroviruses, also includes bovine leukemia virus, a cattle virus that is not an established cause of human illness.) Most people with HTLV-1 never develop symptoms and may never know they carry it. About 5 to 10 percent eventually develop a related condition, often decades after infection. The two most serious are adult T-cell leukemia/lymphoma (ATL), a blood cancer of infected T cells, and HTLV-1-associated myelopathy, also called tropical spastic paraparesis (HAM/TSP), a slowly progressive inflammation of the spinal cord. ATL can show up as swollen lymph nodes, skin rashes or lumps, an enlarged liver or spleen, or a high blood calcium level. HAM/TSP causes increasing stiffness and weakness in the legs, low back pain, and bladder and bowel problems. HTLV-1 can also cause inflammation of the eye (uveitis), persistent skin inflammation, and lung inflammation, and it weakens some immune defenses, which makes certain infections more severe.

Causes & Risk Factors

HTLV-1 spreads through body fluids that contain infected cells. The main routes are breastfeeding from a mother with the virus, sexual contact, sharing needles, and receiving cellular blood products or an organ from an infected donor. It is not spread by casual contact. Mother-to-child transmission happens mostly through breast milk, and longer breastfeeding carries a higher risk. The virus is common in particular parts of the world, including southwestern Japan, the Caribbean, parts of South America (especially Brazil), West and Central Africa, northeastern Iran, and Indigenous communities in central Australia. In the United States it is rare, and infections are found mostly among people from those regions, their sexual partners and their children. In the US and Europe, HTLV-2 is seen mainly among people who inject drugs. All US blood donations have been screened for HTLV since 1988, which has nearly eliminated spread through transfusion. Why only some people with HTLV-1 develop disease is not fully understood. A higher amount of virus in the blood (proviral load) is linked to a higher risk of both ATL and HAM/TSP, and ATL is more common in people who were infected as babies through breastfeeding. Even so, many people with a high viral level never become ill.

How It's Diagnosed

HTLV infection is diagnosed with blood tests, done in two steps. A screening test looks for antibodies, the proteins the immune system makes against the virus. Because a single positive screen is not enough to confirm infection, a second test follows: either a different antibody test (such as a western blot or line immunoassay) or a polymerase chain reaction (PCR) test that detects the virus's genetic material inside blood cells. The confirmatory step also tells HTLV-1 apart from HTLV-2, which matters because their health risks differ. Some people learn they have HTLV after donating blood, during pregnancy screening in countries that test for it, or when a partner or family member is diagnosed. When symptoms suggest a related condition, other tests are added. Diagnosing ATL involves blood counts, a look at blood cells under a microscope, and often a lymph node or bone marrow biopsy, which also determines the subtype. Diagnosing HAM/TSP usually involves a neurological exam, an MRI (magnetic resonance imaging) scan of the spine, and a lumbar puncture (spinal tap) to look for signs of HTLV-1 and inflammation in the fluid around the spinal cord. Eye inflammation is diagnosed by an eye specialist.

Treatment Options

There is currently no treatment that removes HTLV from the body, and no vaccine. For people without symptoms, care usually means understanding the infection, preventing spread to others, and being alert to the signs of related conditions. When a related condition develops, treatment targets that condition. ATL is treated by cancer specialists, and the approach depends on the subtype. Slower-growing (smoldering and chronic) forms generally have a much longer outlook than the aggressive (acute and lymphoma) forms, and treatment is tailored to that difference. The aggressive forms are treated with combination chemotherapy, sometimes with antiviral therapy (zidovudine, an HIV medicine, given with interferon-alpha, an immune-signaling drug), and a stem cell transplant may be an option for some younger, fitter people. These treatments can bring the cancer under control, but aggressive ATL remains difficult to cure. For HAM/TSP, corticosteroids and other medicines that calm the immune system may modestly slow progression, particularly when the disease is active. Much of the day-to-day benefit comes from managing symptoms: medicines for muscle stiffness, treatment for bladder and bowel problems, physical therapy, and walking aids. Uveitis is usually treated with steroid eye drops or other anti-inflammatory treatment from an eye specialist. One precaution matters across these treatments. People with HTLV-1 are prone to a severe form of Strongyloides, an intestinal threadworm that can live in the body unnoticed for years. Steroid treatment in someone with an undetected infection can let the worm multiply rapidly and spread, which can be life-threatening. Testing or preventive treatment for Strongyloides before steroids or other immune-suppressing treatment is a common way to reduce this risk.

What to Expect

For most people with HTLV-1, the infection causes no illness over a lifetime. Estimates of the lifetime risk of ATL range from about 1 to 5 percent, and the risk of HAM/TSP is lower. Daily life is usually unaffected, though learning about a lifelong infection that can be passed to others often raises practical questions about relationships, pregnancy and family. Preventing spread is a central part of living with HTLV-1. Condoms reduce sexual transmission, and people with the virus should not share needles or donate blood, organs, semen or breast milk. For mothers with HTLV-1, feeding a baby formula instead of breast milk prevents the most common route of infection to children, where safe formula is available. Sexual partners and children born to a mother with the virus can be tested. For people who develop a related condition, the course differs a great deal. HAM/TSP usually progresses slowly over years, and many people eventually need a cane or wheelchair; physical therapy and symptom treatment help people stay active and independent for longer. Aggressive ATL can progress quickly, and its outlook is poor, while slow-growing forms may remain stable for years. Regular follow-up with a clinician familiar with HTLV allows problems to be recognized early.

When to Seek Help

Consider an HTLV test if you were born in or have lived in a region where it is common, have a sexual partner or mother with the virus, or are planning a pregnancy with a known risk. If you already know you have HTLV, tell any clinician who is considering steroids or other immune-suppressing treatment. Contact your care team soon if you notice new or worsening stiffness or weakness in your legs, difficulty walking, or new bladder or bowel problems; swollen lymph nodes or a rash or skin lumps that do not go away; or blurred vision, new floaters or eye pain and light sensitivity.

Questions to Ask Your Doctor

  1. 1.Is my infection HTLV-1 or HTLV-2, and what does that mean for my long-term risk?
  2. 2.Would measuring my proviral load or other follow-up tests change how often I should be checked?
  3. 3.How can I protect my partner, and should my partner or children be tested?
  4. 4.What should I know about pregnancy and feeding a baby if I have HTLV-1?
  5. 5.Should I be tested or treated for Strongyloides, especially before any steroid treatment?

Last reviewed • Oct 2026

Educational content, not medical advice.